Table 4.
Clinical VL cases, ELISA-positive cases, and ELISA-negative cases classified by individual's highest ELISA titer obtained during the study period
| Highest IgG titer in the study period (U) | Clinical VL (%) | ELISA positive (%) | ELISA negative (%) | % Clinical rate | Follow-up period in months (SD) |
|---|---|---|---|---|---|
| < 57.9 | 0 (0.0) | – | 448 (100) | 0.0 (0/448) | 29.5 (5.5) |
| ≥ 57.9 to < 1,000 | 9 (22.5) | 86 (88.7) | – | 9.5 (9/95) | 28.8 (6.8) |
| ≥ 1,000 to < 3,000 | 4 (10.0) | 5 (5.2) | – | 44.4 (4/9) | 29.8 (8.3) |
| ≥ 3,000 | 27 (67.5) | 6 (6.2) | – | 81.8 (27/33) | 32.4 (8.0) |
| Total | 40 (100) | 97 (100) | 448 (100) | 6.8 (40/585) | 29.5 (6.0) |
All cases did not have a history of VL before the present study. They were examined three times or more during the study period. The ELISA-positive and –negative cases were without VL symptoms throughout the study.